FDA Makes Official MethylGene’s Partial Clinical Hold On ‘0103 Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
With partner Celgene, the firm had already suspended enrollment in Phase I and Phase II trials due to cases of pericarditis.
You may also be interested in...
MethylGene Revamps Pipeline As Celgene Backs Off HDAC, Sirtuin Collaboration
Firm has high hopes for lifting the clinical hold on MGDC0103.
MethylGene Revamps Pipeline As Celgene Backs Off HDAC, Sirtuin Collaboration
Firm has high hopes for lifting the clinical hold on MGDC0103.
MethylGene Backs Away From Stalled Phase II Cancer Drug
Reworking the MGCD0103 deal with Celgene frees resources for other work.